13 November 2014, 10:50 am
An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates for treatment-naive and treatment-experienced people with genotype 1 hepatitis C virus (HCV), including people with liver cirrhosis and HIV and HCV co-infection, researchers reported on Tuesday at the American Association for the


13 November 2014, 10:40 am
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses shows that by further developing a similar vaccine it may


13 November 2014, 10:40 am
Sofosbuvir/ledipasvir without ribavirin and AbbVie's 3D regimen (paritaprevir/ombitasvir plus dasabuvir) both produced high sustained virological response rates for people with hepatitis C virus (HCV) genotype 4, according to a pair of studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston, USA. HCV genotype 4, the most


12 November 2014, 12:50 pm
A large French study has shown that the vast majority of people living with HIV who started treatment since 2000 in a national cohort achieved a CD4 cell count in the normal range within three to four years of starting treatment, while a large Italian study showed that achieving a normal CD4 count on


12 November 2014, 10:50 am
An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation on Tuesday at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston. Over years or decades, chronic hepatitis C virus (HCV)


1 2
LATEST VIDEOS

TAKE ACTION
UPCOMING EVENTS
    • No upcoming events
  • YOUR NEWS
  • View All Add your news
    YOUR PICTURES
  • LATEST TWEETS